Sesen Bio Inc.

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Sesen Bio (SESN) Stock?

Halozyme Therapeutics

Longeveron

Prothena

Cassava Sciences Inc

Takeda Pharmaceutical

Teva Pharmaceutical

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

Phunware Inc

Transocean

Which penny stocks are you watching this month? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 3 to Watch As December Begins

Beasley Broadcast Group

Foresight Autonomous Hlds

Globalstar

Romeo Power

SNDL Inc.

Wish

Which penny stocks should you watch into 2022? Keep these early-stage companies, fallen angels and turnaround plays on your radar.

7 Penny Stocks with 10x Potential in 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the strengthening of its medical team with the hiring of Dominika Kowalski as Senior Director of Global Drug Safety. Ms. Kowalski's hiring demonstrates Sesen Bio's strong commitment to and continued focus on the development of Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladde

Sesen Bio Strengthens Medical Team

Vinco Ventures

Farmmi

Inspira Technologies Oxy BHN Ltd

REE Automotive Ltd

Penny stocks gaining interest on Reddit to add to your watch list this week. The post 5 Reddit Penny Stocks To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Reddit Penny Stocks To Watch This Week

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Jane Pritchett Henderson, previously a member of Sesen Bio's Board of Directors and the Chair of the Board's Audit Committee, has transitioned off the Board of Directors to a CEO Advisor role, effective November 22, 2021. Ms. Henderson departed the Board in order to concentrate on other responsi

Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role

The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of the BLA. Ahead of the Type A meeting, the burden of proof will be on Sesen's side to show the efficacy of Vicineum post-2017.

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

Fuel Tech

iQSTEL Inc.

Which penny stocks are you watching right now? The post Best Penny Stocks to Buy Now?

Best Penny Stocks to Buy Now? 3 to Watch in Mid-November 2021

Muscle Maker

New Gold

Here's three penny stocks to watch as the market takes a bullish turn The post Top Penny Stocks to Watch as the Market Turns Bullish Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch as the Market Turns Bullish Today

SESEN BIO, INC. (SESN) delivered earnings and revenue surprises of 71.43% and -100.00%, respectively, for the quarter ended September 2021.

SESEN BIO, INC. (SESN) Reports Q3 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the third quarter ended September 30, 2021. During the quarter, the Company continued to work on its path forward to address chemistry, manufacturing, and controls (CMC) and clinical issues identified by the US Food & Drug Administration (FDA) in its Complete Response Letter

Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update

Genius Brands

Are these penny stocks on your watchlist right now? The post Making a Penny Stocks Watchlist Right Now?

Making a Penny Stocks Watchlist Right Now? Check These 3 Out

SESEN BIO, INC. (SESN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

SESEN BIO, INC. (SESN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on October 29, 2021, the Company participated in a productive Type A Meeting with the US Food and Drug Administration (FDA). The purpose of the meeting was to discuss questions related to Chemistry, Manufacturing and Controls (CMC) raised in the FDA's Complete Response Letter (CRL) regarding the

Sesen Bio Announces Productive CMC Type A Meeting with the FDA

Ambev

New Oriental Education & Technology Group

Are these hot penny stocks on your list in October? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 3 to Watch Before Next Month

The stock price of Sesen Bio Inc (NASDAQ: SESN) increased by over 7% pre-market today. This is why it happened.

SESN Stock: Why It Increased Today

Sesen Bio (SESN) stock is rising higher on Wednesday after revealing plans to meet with the U.S. Food and Drug Administration. The post SESN News: Why Biotech Penny Stock Sesen Bio Is Skryocketing Today appeared first on InvestorPlace.

SESN News: Why Biotech Penny Stock Sesen Bio Is Skryocketing Today

The FDA has granted Sesen Bio Inc's (NASDAQ: SESN) request for a Type A meeting to discuss the Chemistry, Manufacturing, and Controls (CMC) issues raised in the Complete Response Letter for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer. Related:   Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch.

Sesen Bio Shares Gain On FDA Type A Meeting On Issues From Vicineum Response Letter

The stock price of Sesen Bio Inc (NASDAQ: SESN) increased by over 15% pre-market. This is why it happened.

SESN Stock: Why The Price Increased By Over 15% Pre-Market

Shares of Sesen Bio Inc. (NASDAQ: SESN) were trading sharply higher following a company announcement that the FDA granted its request for a Type A Meeting to discuss the issues brought up within the complete response letter (CRL) response to Vicineum. Sesen Bio received a CRL response to their bladder cancer candidate Vicineum back on August 16th due to a combination of manufacturing issues and requests for additional data and statistical analyses.

Why Sesen Bio Stock Is Trading Higher Higher During Tuesday's After-Hours Session

Seanergy Maritime Hlds

Best Penny Stocks to Buy Now? Check These 3 Out in October

HyreCar

Boston Beer Company

NEW YORK, NY / ACCESSWIRE / October 18, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for SESN, HYRE and SAM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

New York, New York--(Newsfile Corp. - October 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sesen Bio, Inc. ("Sesen Bio" or the "Company") (NASDAQ: SESN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Sesen Bio securities between December 21, 2020 and August 17, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by...

SESN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Sesen Bio, Inc. Investors With Losses Exceeding $400K of Class Action and Lead Plaintiff Deadline: October 18, 2021

New York, New York--(Newsfile Corp. - October 18, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020 and August 17, 2021, inclusive (the "Class Period"), of the important October 18, 2021 lead plaintiff deadline.SO WHAT: If you purchased Sesen Bio securities during the Class Period you may be entitled to compensation without payment of any out of...

SESN Final Deadline Today: Rosen, Global Investor Counsel, Encourages Sesen Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action - SESN

News for Sesen Bio Inc. Stock (SESN)